Monte Rosa Therapeutics, Inc. GLUE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$130.01M-237% | -$38.63M— | —— | —— | —— | ||
| $8.34M-0.2% | $8.36M+0.3% | $8.33M-0.1% | $8.34M+0.8% | $8.27M+1.9% | ||
| $19.52M+3.5% | $18.87M-0.8% | $19.03M+0.4% | $18.94M+2.1% | $18.55M+2.3% | ||
| —— | —— | —— | —— | $59K— | ||
| —— | —— | —— | -$1.05M-334% | $448K-92.8% | ||
| $6.75M-14.1% | $7.85M+179% | $2.81M+197% | $949K-82.6% | $5.46M+30.6% | ||
| $2.31M+483% | -$604K— | —— | —— | —— | ||
| $87.26M+1,060% | $7.52M-91.9% | $92.66M+446% | -$26.77M-5,433% | $502K-99.4% | ||
| -$1.23M-14.0% | -$1.08M+12.4% | -$1.23M-22.3% | -$1.01M+13.2% | -$1.16M+13.9% | ||
| $3.57M-25.6% | $4.79M+9.7% | $4.37M+186% | $1.53M+71.0% | $893K+369% | ||
| -$14.68M+35.6% | -$22.8M-115% | $149.14M+438% | $27.72M-20.1% | $34.67M-17.4% | ||
| $4.98M+6.0% | $4.7M+14.2% | $4.12M+6.5% | $3.86M-7.8% | $4.19M+5.1% | ||
| —— | —— | —— | —— | —— | ||
| $10.23M+78.8% | $5.72M+4,791% | $117K0.0% | $117K-85.9% | $829K-21.9% | ||
| —— | —— | —— | —— | —— | ||
| $358.67M+1,082% | $30.35M+2,173% | $1.34M+33.2% | $1M-99.0% | $98.66M-0.2% | ||
| —— | —— | —— | —— | —— | ||
| $8.34M-0.2% | $8.36M+0.3% | $8.33M-0.1% | $8.34M+0.8% | $8.27M+1.9% | ||
| $6.75M-14.1% | $7.85M+179% | $2.81M+197% | $949K-82.6% | $5.46M+30.6% | ||
| —— | —— | —— | —— | —— | ||
| $87.26M+1,060% | $7.52M-91.9% | $92.66M+446% | -$26.77M-5,433% | $502K-99.4% | ||
| -$1.23M-14.0% | -$1.08M+12.4% | -$1.23M-22.3% | -$1.01M+13.2% | -$1.16M+13.9% | ||
| $3.57M-25.6% | $4.79M+9.7% | $4.37M+186% | $1.53M+71.0% | $893K+369% | ||
| $2.31M+483% | -$604K— | —— | —— | —— | ||
| —— | $7M+33.3% | $5.25M+50.0% | $3.5M+100% | $1.75M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$1.23M-14.0% | -$1.08M+12.4% | -$1.23M-22.3% | -$1.01M+13.2% | -$1.16M+13.9% | ||
| —— | —— | —— | —— | —— | ||
| -$19.66M+28.5% | -$27.5M-119% | $145.02M+508% | $23.85M-21.7% | $30.48M-19.8% | ||
| -$19.66M+28.5% | -$27.5M-119% | $145.02M+508% | $23.85M-21.7% | $30.48M-19.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Monte Rosa Therapeutics, Inc. generate?
- Monte Rosa Therapeutics, Inc. (GLUE) generated -$14.7M in operating cash flow over the trailing twelve months.
- What is Monte Rosa Therapeutics, Inc.'s free cash flow?
- After $5.0M of capital expenditures, Monte Rosa Therapeutics, Inc.'s free cash flow was -$19.7M over the trailing twelve months, down 164.5% year over year.
- Where does Monte Rosa Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
